论文部分内容阅读
发改委网站2009年11月23日发布了《关于印发改革药品和医疗服务价格形成机制的意见的通知》,宣布将调整政府管理药品价格范围,实行分级管理,规范药品定价机制,鼓励药企在不突破政府管理价格的前提下,依据市场供求自主定价。“高诊费、低药费”是此次改革的一个方向,通知提出,要逐步降低政府指导价药品的流通差价率,对流通环节差价率(额)实行上限控制,并对高价和低价药品实行差别差率控制,低价药品差价率从高,高价药品差价率从低,利用价格杠杆促进药品流通领域兼并重组,扩大规模,集约经营,降低成本,减少流通费用。改革还鼓励药品研发创新,在合理审核药品成本基础上,根据药品创新程度,对销售利润实行差别控制。允许创新程度较高的药品在合理期限内保持较高销售利润率,促进企业研制开发创新药品。
On November 23, 2009, the NDRC website promulgated the “Circular on Issuing Opinions on Reforming the Mechanism of Price Formation for Pharmaceuticals and Medical Services”, announcing that it will adjust the range of government-administered drug prices, implement a hierarchical management, standardize the drug pricing mechanism, Break through the government management of the premise of price, based on market supply and demand independent pricing. “High clinic fees, low drug ” is a direction of this reform, the circular proposed that we should gradually reduce the government guidance price of drugs, the spread of the spread rate (amount) the implementation of the ceiling control, and the high price and The implementation of differential rate control of low-cost drugs, low-cost drug rates from high, high drug prices from low, the use of price leverage to promote mergers and acquisitions in the field of drug circulation, expand the scale and intensive management, reduce costs and reduce circulation costs. The reform also encouraged the R & D and innovation of medicines. On the basis of a reasonable examination of the cost of medicines, differences in sales profits were controlled according to the degree of drug innovation. Allow a more innovative drugs to maintain a high sales profit margin within a reasonable period of time, and promote enterprises to develop innovative drugs.